Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aurinia Pharmaceuticals (AUPH) Reports In-Line Q1 EPS
May 14, 2020 4:34 PM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $30 thousand versus the consensus estimate of $50 thousand.
We are fortunate that the global COVID-19 pandemic has had minimal impact on Aurinias operations, and we have maintained our timelines to ensure the filing of the voclosporin NDA by the end of the... More
